Insufficient capital to fund operations and development
The company states it may need to delay, scale back, or cease programs if it cannot raise funds on acceptable terms.
- Scope
- R&D, commercialization and corporate operations
- Materiality
- high
Dare Bioscience, Inc.
Dare Bioscience, Inc. is a women’s health biopharmaceutical company developing and commercializing proprietary products across contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health, and menopause. The company is shifting from a pure development model toward a capital-efficient commercialization model that combines late-stage R&D with near-term revenue opportunities through Section 503B compounded products and consumer health offerings.
−1 156,9 %
71,3 %
−1 300,7 %
+10 429,4 %
1.14
1.14
| % | |
|---|---|
| Commercialized and near-term commercial products | 20% Includes XACIATO and planned Section 503B/consumer health offerings such as DARE to PLAY Sildenafil Cream and DARE to RESTORE. |
| Late-stage women’s health product candidates | 35% Includes Ovaprene and DARE-HRT1, which are being advanced toward clinical and commercial milestones. |
| Early-stage clinical and preclinical programs | 25% Includes DARE-VVA1, DARE-HPV and other pipeline assets still in development. |
| Grant-funded development programs | 20% Programs supported by non-dilutive grants, including work tied to DARE-LARC1, Ovaprene and DARE-HPV. |
Dare’s direct customers are healthcare providers, outsourcing facilities, telehealth partners, and third-party...
- Women’s health providersprimary
Prescribe or recommend products such as Sildenafil Cream, XACIATO and future pipeline therapies because they address unmet women’s health needs.
- Telehealth and consumer health partnersprimary
Help market and distribute non-prescription products like DARE to RESTORE and support direct-to-consumer awareness.
- 503B outsourcing facilitiesprimary
Manufacture and dispense compounded products under the company’s Section 503B strategy.
- Women patients and consumersprimary
Buy or use the products for contraception, sexual health, vaginal health, menopause and related conditions.
- Strategic collaborators and grant funderssecondary
Provide non-dilutive funding, development support, or commercialization access for specific programs.
The company is headquartered in the United States and its near-term commercial plans are centered on the U.S. market...
- •United States is the main market for prescription and consumer launches
- •U.S. FDA regulatory pathway drives development and commercialization timing
- •European sourcing supports vaginal probiotic consumer health products
- •No disclosed country revenue breakdown in the provided excerpts
- •Geographic exposure is concentrated in U.S. clinical and commercial execution
Dare is pursuing a capital-efficient transition from a development-stage biotech into a company with near-term...
01
Launch near-term commercial productsshort-term
Creates initial revenue and market presence without building a full sales infrastructure.
02
Pursue capital-efficient commercializationshort-term
The company lacks internal sales and distribution capabilities, so partnerships reduce fixed costs and execution risk.
03
Advance late-stage women’s health pipelinemedium-term
Clinical progress supports future FDA-approved products and longer-term value creation.
04
Reduce dependence on dilutive capitalmedium-term
Management wants commercial and grant funding to help fund operations and reduce financing pressure.
The company remains highly dependent on external capital, clinical success and execution of a still-developing...
Nasdaq listing compliance
Failure to meet continued listing standards could impair liquidity and access to capital.
- Scope
- Equity financing and market confidence
- Materiality
- high
Clinical development and regulatory approval risk
Pipeline value depends on successful IND filings, clinical studies and FDA outcomes.
- Scope
- Ovaprene, DARE-HRT1, DARE-VVA1, DARE-HPV
- Materiality
- high
Commercial launch and adoption risk
Near-term products may not generate meaningful revenue if provider adoption or consumer demand is weak.
- Scope
- DARE to PLAY Sildenafil Cream, DARE to RESTORE™, DARE-HRT1
- Materiality
- high
Dependence on third parties
The company relies on outsourcing facilities, collaborators and marketing partners rather than owned infrastructure.
- Scope
- Manufacturing, distribution and commercialization
- Materiality
- medium
Grant accounting and deferred grant funding
Affects cash, liabilities and the timing of R&D expense recognition
Going-concern assessment
Can affect disclosure, valuation assumptions and investor risk perception
Milestone and in-license obligations
Can create lumpy operating expenses or accrued liabilities
Stock-based compensation
Impacts reported operating loss and non-cash expense trends
: 28.4.2026